ARTV

Artiva Biotherapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth 4/10
  • Value 4/10
Artiva Biotherapeutics sales and earnings growth
ARTV Growth
Neutral
  • Revenue Y/Y 0.00%
  • EPS Y/Y 84.20%
  • FCF Y/Y -31.61%
Artiva Biotherapeutics gross and profit margin trends
ARTV Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y 0.00%
Artiva Biotherapeutics net debt vs free cash flow
ARTV Risk
Great
  • Debt / Equity 0.1
  • Debt / FCF 0.0
  • Interest coverage NA

Artiva Biotherapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks